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Abstract: Prostate cancer is one of the most common cancers diagnosed in men in the United States
and the second leading cause of cancer-related deaths worldwide. Since over 60% of prostate cancer
cases occur in men over 65 years of age, and this population will increase steadily in the coming
years, prostate cancer will be a major cancer-related burden in the foreseeable future. Accumulating
data from more recent research suggest that the tumor microenvironment (TME) plays a previously
unrecognized role in every stage of cancer development, including initiation, proliferation, and
metastasis. Prostate cancer is not only diagnosed in the late stages of life, but also progresses
relatively slowly. This makes prostate cancer an ideal model system for exploring the potential of
natural products as cancer prevention and/or treatment reagents because they usually act relatively
slowly compared to most synthetic drugs. Resveratrol (RSV) is a naturally occurring stilbenoid
and possesses strong anti-cancer properties with few adverse effects. Accumulating data from
both in vitro and in vivo experiments indicate that RSV can interfere with prostate cancer initiation
and progression by targeting the TME. Therefore, this review is aimed to summarize the recent
advancement in RSV-inhibited prostate cancer initiation, proliferation, and metastasis as well as
the underlying molecular mechanisms, with particular emphasis on the effect of RSV on TME. This
will not only better our understanding of prostate cancer TMEs, but also pave the way for the
development of RSV as a potential reagent for prostate cancer prevention and/or therapy.
Keywords: resveratrol; prostate cancer; tumor microenvironment; stroma
1. Introduction
For men, prostate cancer is the second most common cancer in the world, resulting
in over 350,000 deaths in 2018 [1]. Most prostate cancers are adenocarcinoma, originating
from epithelial cells in the peripheral zone of the prostate [2]. The survival rate for patients
with prostate cancer confined to the primary site is nearly 100% [3]. If left unchecked,
prostate cancer progresses and eventually metastasizes to form new cancers in other tissues
throughout the body. The overwhelming majority of prostate cancer–related deaths occur
due to metastasis, most often to the bone [4]. Since prostate cancer incidence increases
exponentially for men over 65 years, and this population will increase dramatically in the
coming years, prostate cancer is expected to be a big burden both socially and economically
in the foreseeable future [1].
Because of the importance of the androgen/androgen receptor (AR) signaling path-
way in prostate cancer initiation and progression [5], most basic and clinical research
has been focused on the androgen/AR axis. Androgens such as testosterone and dihy-
drotestosterone bind AR in the cytoplasm and the ligand-bound AR is translocated to the
nucleus to interact with AR responsive elements (ARE) and transcriptionally regulate the
expression of AR target genes such as prostate-specific antigen (PSA) [6]. Dysregulation of
the androgen/AR axis can lead to cancer cell proliferation, escaping from apoptosis, and
metastasis [7,8]. Multiple lines of evidence from recent research indicate that, in addition
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to the androgen/AR axis, the tumor microenvironment (TME) plays an indispensable role
in prostate cancer initiation and progression [9,10]. The TME is composed of fibroblasts,
the extracellular matrix (ECM), immune cells, and other factors in the tumor cell’s sur-
roundings [11]. There is constant communication between tumor cells and the TME [12].
Fibroblasts, especially cancer-associated fibroblasts (CAFs), play important roles in each of
the developmental stages of different cancers, including prostate cancer [9,13]. In fact, AR
signaling is not only involved but also plays an important role in TME [14,15], although the
extent of and exact mechanisms involved in AR-mediated changes in TME are still being
elucidated.
Compared to most other cancers, prostate cancer progression is usually much slower,
so the most common approaches taken with early and low-risk prostate cancers are non-
invasive active surveillance and watchful waiting [16]. Advanced prostate cancer is treated
with radical prostatectomy, radiotherapy, chemotherapy, and androgen-deprivation ther-
apy (ADT) through physical or chemical castration to repress androgen-induced AR sig-
naling [17]. Although responsive to ADT at the beginning, most prostate cancers become
ADT-resistant over time [18] due to the formation of constitutively active AR variants or the
activation of AR by other factors [9]. For castration-resistant prostate cancer (CRPC) [19],
treatment is usually the combination of traditional ADT and second-line antiandrogen
drugs such as abiraterone acetate, an androgen synthesis inhibitor, or enzalutamide, to
inhibit AR directly [20,21]. Accumulating data demonstrate that resveratrol (RSV), a stil-
benoid produced in multiple plants, possesses strong anti-cancer properties [22,23]. By
targeting both AR [24] and the TME [25,26], RSV can induce growth inhibition, cell cycle
arrest, apoptosis, as well as inhibit metastasis of different cancer types, including prostate
cancer [22,27]. More importantly, since RSV has few side effects at therapeutic concentra-
tions, it can be used as a treatment regimen without fear of complications [28]. To pave
the road for the development of RSV as a preventive and/or therapeutic reagent, either by
itself or in combination with other drugs, our review focuses on the effects of RSV on the
TME in prostate cancer initiation, proliferation, and metastasis.
2. RSV Inhibits Prostate Cancer Initiation by Targeting the TME
The exact point at which prostate tissue transitions from normal to cancerous as well
as the underlying molecular mechanisms remain ambiguous. However, multiple factors,
including the TME, play important roles in the initiation of tumors, including those in the
prostate. Although different components of the TME have their roles in cancer development,
the communication between the prostate stromal and epithelial cells plays an indispensable
role in prostate cancer initiation. Results from research using a mouse model to study
cancer initiation in submandibular glands indicate that the interaction between stroma and
epithelium is essential because malignancy only occurred when stromal and epithelial cells
grew together [29]. Following suit, Chung et al. demonstrated the essentiality of stromal
cells in prostate cancer initiation [30]. Since transitional carcinoma cells from mice bladder
can grow together with embryonic urogenital sinus mesenchyme (UGM), UGM was used
to mimic the reactive human prostate stroma to induce prostatic neoplasms. These results
indicate that crosstalk between the stromal and epithelial cells not only exists but also is
imperative for the initiation of prostate neoplasia. However, since humans have a much
higher proportion of smooth muscle and overall stromal cells than mice [31], this difference
needs to be taken into consideration for any solid conclusions about the role of stroma in
prostate cancer initiation. Therefore, similar studies in humans will be an important step
for an accurate depiction of reactive stroma in prostate cancer initiation.
The development of prostate cancer is very similar to the development of benign
prostate hyperplasia (BPH) because they share similarities at the molecular, cellular, ge-
netic, hormonal, and inflammatory levels [32]. Therefore, studying the initiation of benign
prostate hyperplasia may also provide insight into prostate cancer initiation. Hayward
et al. performed a tissue recombination study by co-culturing benign prostate epithelial
cells with stromal cells from either BPH or normal prostate tissues [33] and found that sig-
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nificant epithelial proliferation occurred only when co-cultured with BPH stromal cell lines,
indicating that stromal cells have an important role in BPH development. It is important
to note that although stromal cells can influence the development of malignancy [34], the
communication between the stroma and epithelium is bidirectional. Epithelium-derived
cancer cells are capable of influencing the stroma, specifically that of the smooth muscle.
Co-culturing of 18-day embryonic rat UGM tissue with either normal epithelial cells or
neoplastic prostate epithelial cells showed that the cells from the normal epithelia induce
ductal structure formation in smooth muscle, while the cells from neoplastic prostate
epithelia failed to do so [33]. These findings altogether indicate that the stromal cells play
an important role in prostate cancer initiation, and malignant cells are capable of affecting
stromal cell behavior. Given the importance of stroma–epithelium crosstalk in prostate
cancer initiation, interrupting this communication could be a plausible strategy in the
prevention of prostate cancer initiation [35].
Although multiple lines of evidence indicate that stroma–epithelium crosstalk is
essential in the initiation of prostate cancer, the exact role of stromal cells in prostate cancer
initiation is currently unknown. Based on the fact that the stromal cells in non-cancerous
tissues are more stable than in cancerous tissues, it has been postulated that it is the cancer-
associated fibroblasts (CAFs), not the normal stromal cells, that induce tumor initiation [35].
Cunah et al. engrafted BPH-1 cells with either normal stroma or CAFs to adult male mice
and found that tumors formed only when the cells were co-engrafted with CAFs [36].
Therefore, it is hypothesized that the CAFs may secrete excess growth factors and/or
cytokines to protect the tumor cells from apoptotic death and subsequently lead to tumor
formation [37]. As depicted in Figure 1, CAFs secrete more transforming growth factor-
beta (TGF-β) than the normal stroma [38]. By activating TGF-β Receptor II (TBRII), the
TGF-β can enhance cell proliferation, differentiation, and extracellular matrix production.
Given that the prostate epithelial cells are TGF-β Receptor II (TBRII)-positive [39], it is
fully conceivable that TGF-β/TBRII can mediate the communication between CAFs and
prostate epithelial cells (Figure 1).
Since the cancer-preventive effects of RSV were first reported in 1997 [22], both epi-
demiological and case-controlled studies have demonstrated that RSV and/or consumption
of foods/drinks with high levels of RSV can reduce prostate cancer incidence [40]. These
findings suggest that RSV could potentially inhibit prostate cancer initiation. Based on
the role of CAFs in prostate cancer initiation, early research was focused on the effect
of RSV on CAFs. To determine if RSV can inhibit CAF-induced prostate cancer initia-
tion, Wen et al. examined the effect of RSV on TGF-β secretion and found that RSV is
capable of downregulating TGF-β expression from CAFs [8]. Further research demon-
strated that the downregulation of TGF-β is partially due to RSV’s repressive effect on
the Wnt/Beta-catenin pathway [41]. Given that the Wnt pathway in prostate epithelial
cells can be activated by CAFs, and RSV is capable of inhibiting TGF-β secretion from
CAFs, RSV is likely to inhibit prostate cancer initiation by targeting the TGF-β/TBRII
axis. Also, activation of the JAK2/pSTAT1 pathway activates mast cells, leading to in-
flammation and the transition of stroma to CAFs [42]. Since RSV can cause mast cells
to reduce fibrosis by targeting the SCF and c-kit pathway [43], it is also likely that RSV
inhibits prostate cancer initiation through repression of mast cell–mediated stromal cell
transition to CAFs (Figure 1). However, to demonstrate that RSV can inhibit prostate cancer
initiation unambiguously, it is important to conduct both in vitro and in vivo experiments
to demonstrate RSV’s role in inhibiting prostate cell cancerization.
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Figure 1. RSV inhibits prostate cancer initiation (A) CAFs- secreted TGF- β interacts with its recep-
tors TBRII on prostate cells drives tumor initiation (B) and RSV is capable of inhibiting this pro-
cess. 
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3. RSV Inhibits Prostate Cancer Cell Proliferation by Targeting the TME
Tw of the most fundamental trait of cancer cells are eir abilities to proliferate
without regulatio and evade cell death [44], d both of thes traits ca be m diated
by the TME. As described in the previous section, crosstalk between the strom and
epithelium under tumorigenic conditions is a key d iver in prostate cancer growth [44,45].
The normal fibroblasts acquire a modified phenotype (ph noc nversio ) and bec me
perpetually activat CAFs [46,47]. The normal fibroblasts secrete only enough f ctors
to maintain normal tissue function and have a relatively low proliferative potential [48].
But the increased secretion of growth factors and cytokines by the CAFs [49] exposes
the tumor cells to an altered TME favoring cell growth and proliferation. Therefore, the
transition of pre-carcinogenic stroma to CAFs is a critical mechanism for prostate cancer
cell proliferation and cancer progression.
3.1. RSV Inhibits Prostate Cancer Proliferation by Interrupting St oma–Tumor Cell
Communication
It has been shown that RSV can ffect the prolifer tion of prostate cancer cells both
in itro and in vivo. For example, treating androgen-responsive h man prostate cancer
cells (LNCaP) with different concentrations of RSV demonstrated that RSV can inhibit
cancer cell proliferation in a concentration-dependent manner. One possible explanation is
that RSV targets the AR- and ER-dependent signaling pathways because RSV is capable
of counteracting both androgen- and estrogen-induced cell growth [50]. RSV also can
inhibit prostate cancer cell proliferation in both transgenic rat adenocarcinoma of prostate
(TRAMP) mouse and tumor xenograft models. Harper et al. showed that when transgenic
mice were fed a diet containing RSV, cell proliferation in the dorsolateral prostate and
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ventral prostate decreased significantly [51]. The authors also observed that the transgenic
mice had a marked increase (42–62%) of well-differentiated prostate tumors compared to
the control animals, suggesting that RSV can halt tumor progression. Wang, et al. injected
LNCaP cells into mice on an RSV-enriched diet and found that RSV can delay tumor growth.
Of note, both Harper and Wang’s studies suggest that RSV targeted the hormone-based
signaling pathways [50,51]. However, the RSV-mediated delay was only temporary, as
the tumor volumes of the xenograft mice fed RSV eventually caught up with those of the
controls. The underlying mechanisms remain unknown.
Increased levels of interleukin-6 (IL-6) have been linked to poor survival among
prostate cancer patients, and it is known that CAFs secrete high levels of IL-6 into the
TME. One of the signaling pathways activated by IL-6 is JAK/STAT3. Activation of
this pathway in the cells leads to tumor cell proliferation and escape from apoptosis.
Mechanistically, the IL-6-activated JAK leads to STAT3 dimerization and translocation
to the nucleus to upregulate the expression of proliferative proteins like Bcl-x and Mcl-
1 [52,53]. These anti-apoptotic proteins collectively (Figure 2) prevent cell death by reducing
mitochondrial outer membrane permeability [54]. When LNCAP and 22RV1 cells were
treated with IL-6, the STAT3 was phosphorylated and activated [55], accompanied by
enhanced cell proliferation. Consistently, the activity of the IL-6/STAT3 signaling pathway
is proportional to the growth rate of advanced prostate cancer [56]. Additionally, it has been
found that in LNCAP cells the IL-6-activated JAK/STAT3 pathway also downregulates
p53, a major cell cycle regulator [57,58]. Multiple lines of evidence indicate that the
CAF-secreted IL-6 may also influence tumor growth by affecting AR activity. Hobisch
et al. first observed that in prostate cancer cells IL-6 can activate AR in a dose-dependent
manner [59]. Soon after, it was found that in LNCaP cells the IL-6-upregulated serine-
threonine kinase Pim1 can phosphorylate (serine-213) and activate AR [60,61]. In addition,
Kemskova et al. demonstrated that Pim1 is also regulated by STAT3. These findings
altogether indicate that the IL-6/JAK/STAT3 pathway can enhance prostate cancer cell
proliferation in an AR-dependent manner [62] (Figure 2). Therefore, monoclonal and
immunotherapeutic treatments targeting the IL-6/JAK/STAT3 pathway are currently
under vigorous investigation [55,63].
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Figure 2. RSV inhibits prostate cancer proliferation. Hypoxia-induced HIF1α and activation of 
JAK/STAT by the CAFs- secreted IL-6 enhance tumor growth, and RSV is capable of inhibiting cell 
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RSV also indirectly affects IL-6 signaling by inhibiting its downstream factor STAT3 to 
mitigate proliferative effects. For example, experimental results from mouse fibroblast 
(NIH3T3) cells and LNCaP cells showed the inhibitory effect of RSV on Src tyrosine ki-
Figure 2. RSV inhibits prostate cancer proliferation. Hypoxia-induced HIF1α and activation of JAK/STAT by the CAFs-
secreted IL-6 enhance tumor growth, and RSV is capable of inhibiting cell proliferat on.
It has been reported that RSV can exert a strong anti-proliferative and pro-apoptosis
eff ct on the CAFs in both p osta e and lung canc cell lines [64]. Meanwhile, RSV blunts
and even reverses phe oco version from normal prostate fibroblast to myofibroblast. RSV
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also indirectly affects IL-6 signaling by inhibiting its downstream factor STAT3 to mitigate
proliferative effects. For example, experimental results from mouse fibroblast (NIH3T3) cells
and LNCaP cells showed the inhibitory effect of RSV on Src tyrosine kinase, an activator
of STAT3, repressing the STAT3 signaling pathway [65,66] and subsequently reducing cell
growth and increasing apoptosis (Figure 2). The authors posit that apoptosis is triggered by
downregulating downstream factors like Bcl-x, Mcl-, and Cyclin D1 [67,68]. Furthermore,
Lee et al. demonstrated that inhibiting IL-6 RSV can repress STAT3-upregulated AR and cell
proliferation in prostate cancer cells [25].
3.2. RSV Inhibits Cancer Cell Proliferation by Affecting Hypoxic Conditions of the TME
It is well established that aerobic glycolysis, also known as the Warburg effect, occurs
in cells of solid tumors. Hypoxia and high acidity are the two main characteristics of
the Warburg effect, and both of them favor the proliferation of cells in solid cancer [69].
Numerous signaling pathways in prostate cancer cells respond to the hypoxic TME, and
these pathways collectively lead to increased angiogenesis, survival, proliferation, and/or
metastasis [70]. Hypoxia-inducible factor 1-α (HIF1α) plays a central role in cellular
adaptation to hypoxic conditions. In hypoxia, the stabilized HIF1α transcriptionally
regulates the pro-proliferative and anti-apoptotic genes [71]. Meanwhile, O2 is more
frequently reduced to reactive oxygen species (ROS), such as superoxide (O2−) [72,73],
which can further stabilize HIF1α [74,75]. Understanding the mechanisms by which tumor
cells proliferate in response to the hypoxic TME may prove advantageous for targeted
inhibition of cancer cell proliferation.
RSV appears to be both pro- and anti-oxidant, depending on the circumstances [76].
In non-cancer tissues, RSV serves as an antioxidant [77], and therefore RSV can exert a
beneficial effect on a wide variety of issues, including neuronal [78], anti-inflammatory [79],
and cardiac [80]. However, to cancer cells with low pH environments due to the Warburg
Effect, RSV shows more pro-oxidant characteristics. Shamim et al. found that RSV can
induce cancer cell death by inducing ROS accumulation, which subsequently leads to
oxidative DNA damage and apoptosis [81–83]. Using the TRAMP model, Wang et al.
demonstrated that RSV-enhanced cancer cell death is due to the upregulation of HIF1α,
which enhances ROS concentration in the TME beyond the limit for survival [84]. Since RSV
preferentially increases superoxide over other ROS species like hydrogen peroxide [85],
Low et al. expounded on the pro-apoptotic effects of elevated superoxide levels in the
mitochondria [86] and found that superoxide can activate caspases 9 and 3, and subse-
quently promote the release of cytochrome C and apoptosis (Figure 2). It is important to
note that low concentration of RSV can serve as a pro-oxidant that favors cell survival,
and pro-apoptotic effects occur only at relatively higher RSV concentrations to stimulate
superoxide production. The bidirectional nature of RSV needs to be considered when RSV
is used as a therapeutic reagent.
4. RSV Inhibits Prostate Cancer Metastasis by Targeting the TME
The migration of cells in solid cancers toward their surrounding tissues is the first
step of metastasis. Migratory cancer cells undergo both molecular and cellular changes in
response to their TME. These changes are collectively known as epithelial-mesenchymal
transition (EMT), in which the epithelial cells lose their cell–cell adhesion and gain migra-
tory and invasive properties. Generally, the stroma in non-cancer tissues is rather stable.
However, both genetic and epigenetic changes have been found in CAFs [87]. Given that
constant communication occurs between stromal cells and cancerous epithelial cells [13],
it is conceivable that CAFs could affect the migratory properties of the cancer cells. Mul-
tiple lines of evidence indicate that the CAFs are capable of promoting EMT [30,87] and
consequently enhance cancer cell migration and invasion [88,89]. Therefore, understand-
ing stroma-mediated EMT is of importance not only in understanding the underlying
molecular mechanism but also for identifying potential agents to prevent or even reverse
metastasis [89].
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4.1. Resveratrol Interrupts the Communication between Stromal and Cancer Cells
One of the effects that CAFs exerted on cancer cells to enhance EMT is to secret dif-
ferent factors into the TME, which are subsequently sensed by cancer cells [90]. Indeed,
the level of hepatocyte growth factor (HGF) in the TME of metastatic prostate cancer is
higher than that of non-metastatic cancers [90]. Glenn A. Gmyrek et al. [91] have experi-
mentally demonstrated that HGF is capable of triggering pro-migratory phosphorylation
of prostate cancer cells and enhancing migration and metastasis. The same group of re-
searchers further demonstrated that the cultured stromal cells showed a myofibroblastic
phenotype and speculated that the myofibroblastic subpopulation of prostate stromal cells
could be the source of HGF in vivo [91]. Further analysis found that in prostate tissues the
HGF is expressed in the stromal cells but not the epithelium, suggesting the HGF in the
TME could be the result of paracrine secretion. Since CAFs secrete higher levels of HGF
than normal stromal cells, the CAFs were postulated as the culprits driving cancer cell
migration [26,91]. Later, it was experimentally demonstrated that stromal cells are capable
of enhancing prostate cancer cell migration and that this effect is HGF-dependent [92].
Mechanistically, the CAF-derived HGF interacts with c-Met receptors on cancer cells to
activate numerous signaling pathways, especially those related to EMT and metastasis [90]
(Figure 3). Therefore, any strategies interrupting the HGF/c-Met interaction by either
inhibiting the secretion of HGF or repressing the cancer cell responses to HGF could inhibit
EMT and metastasis. To determine if RSV can repress stromal cell–mediated prostate cancer
migration, Hsieh TC et al. co-cultured stromal and cancer cells in the presence or absence
of RSV and found that RSV can indeed inhibit stromal cell–enhanced cancer cell migration.
Since treatment of the co-culture with either RSV or antibodies specifically against HGF
abolished stroma-enhanced migration to a similar degree, the authors proposed that RSV
inhibits cancer cell migration by counteracting the stromal cell–derived HGF [92]. These
findings altogether indicate that (1) stromal cell–secreted HGF plays important roles in
prostate cancer migration and invasion, and (2) RSV inhibits prostate cancer migration at
least partially by counteracting HGF (Figure 3).
J. Xenobiot. 2021, 2, FOR PEER REVIEW 7 
 
One of the effects that CAFs exerted on cancer cells to enhance EMT is to secret dif-
ferent factors into the TME, which are subsequently sensed by cancer cells [90]. Indeed, 
the level of hepatocyte growth factor (HGF) in the TME of metastatic prostate cancer is 
higher than that of non-metastatic cancers [90]. Glenn A. Gmyrek et al. [91] have experi-
mentally demonstrated that HGF is capable of triggering pro-migratory phosphorylation 
of prostate cancer cells and enhancing migration and metastasis. The same group of re-
searchers further demonstrated that the cultured stromal cells showed a myofibroblastic 
phenotype and speculated that the myofibroblastic subpopulation of prostate stromal 
cells could be the source of HGF in vivo [91]. Further analysis found that in prostate tis-
sues the HGF is expressed in the stromal cells but not the epithelium, suggesting the HGF 
in the TME could be the result of paracrine secretion. Since CAFs secrete higher levels of 
HGF than normal stromal cells, the CAFs were postulated as the culprits driving cancer 
cell migration [26,91]. Later, it was experimentally demonstrated that stromal cells are 
capable of enhancing prostate cancer cell migration and that this effect is HGF-dependent 
[92]. Mechanistically, the CAF-derived HGF interacts with c-Met receptors on cancer cells 
to activate numerous signaling pathways, especially those related to EMT and metastasis 
[90] (Figure 3). Therefore, any strategies interrupting the HGF/c-Met interaction by either 
inhibiting the secretion of HGF or repressing the cancer cell responses to HGF could in-
hibit EMT and metastasis. To determine if RSV can repress stromal cell–mediated prostate 
cancer migration, Hsieh TC et al. co-cultured stromal and cancer cells in the presence or 
absence of RSV and found that RSV can indeed inhibit stromal cell–enhanced cancer cell 
migration. Since treatment of the co-cult re with either RSV or antibodies specifically 
against HGF olished stroma-enhanced migration to a similar degree, the authors pro-
posed that RSV inhibits cancer cell migration by counteracting the stromal cell–derived 
HGF [92]. These findings altogether indicate that (1) stro l r ted HGF plays im-
portant roles in pros ate cancer migration and invasi ,    inhibits prostate can-
cer migration at least partially by counteracting HGF (Figure 3). 
 
Figure 3. RSV inhibits EMT and cancer cell metastasis. The CAFs-released TGF-, VEGF and HGF 
(A) interact with their corresponding receptors on cancer cells and enhance EMT processes (B). 
The cancer cells metastasize from their primary site (B) to the bone (C). RSV is capable of inhibit-
ing prostate cancer metastasis by repressing EMT and cancer cell migration/invasion. 
Figure 3. RSV inhibits EMT and cancer cell metastasis. The CAFs-relea ed TGF-β, VEGF and HGF (A) interact with
their corresponding receptors on cancer cells and enhance EMT processes (B). The cancer cells metastasize from their
primary site (B) to the bone (C). RSV is capable of inhibiting prostate cancer metastasis by repressing EMT and cancer cell
migration/invasion.
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It is well known that the ion channel transient receptor potential ankyrin 1 (TRPA1)
on CAFs is one of the main control mechanisms for HGF secretion. To further understand
the mechanism of RSV-inhibited cancer migration, both mouse [93] and rat [94] models
were used, and the results demonstrated that RSV can block HGF secretion by inhibiting
TRPA1. Additionally, Vancauwenberghe et al. [26] further demonstrated that by inhibiting
the TRPA1, RSV is capable of blocking the secretion of both HGF and vascular endothelial
growth factor (VEGF), an important factor involving the angiogenesis of tumor tissues.
These findings altogether suggest that RSV could be potentially used as a reagent to inhibit
prostate cancer metastasis (Figure 3). Of note, this same study [89] also noticed that RSV
can exert an opposite effect on cells expressing a mutant TRPA1, which not only increased
expression and secretion of HGF and VEGF, but also enhanced prostate cancer metastasis.
Therefore, it is important to stratify prostate cancer patients based on their TRPA1 types
and apply RSV only to those with wild-type TRPA1.
4.2. Resveratrol Inhibits Prostate Cancer Metastasis by Targeting the Extracellular Matrix
The extracellular matrix (ECM) is a network formed between cells composed of non-
cellular components such as protein, glycosaminoglycan, and glycoconjugate. The ECM
can provide both structural and biochemical support to the resident cells, and therefore
the ECM can affect cellular behaviors. One of the largest components of the ECM is
collagen, which is synthesized and secreted by fibroblasts located in the stroma [95].
Communication between collagen and cancer cells exists in every cancer development
stage [96]. Additionally, cadherin plays important structural and signaling roles in cell–cell
and cell–ECM interactions [97]. E-cadherin usually maintains the integrity of epithelial
tissue, and N-cadherin mediates the contact between cells and the matrix. During the
EMT process, N-cadherin is usually upregulated with concurrent downregulation of E-
cadherin [98]. Combined dysregulations make the tumor cells more motile and favor
metastasis, thereby allowing cancer cells to escape from the site of origin. Therefore, the
ECM is an additional barrier to break before the cancer cells can escape from the TME.
Activation of the PI3K signaling pathway can lead to collagen production and fibro-
sis [99]. The transforming growth factor beta-1 (TGFβ-1), secreted from human prostate
stromal cells, can reactivate the stroma by stimulating the phenotypic switch of fibroblasts
to myofibroblasts, thus further increasing collagen secretion [95]. It has been shown that
RSV can inhibit both the TGFβ and PI3K signaling pathways, thereby decreasing the
production and secretion of collagen from the stroma. Since collagen is so prevalent in both
benign and malignant tissue, it has been shown that, in organs with highly collagenous
reactive stroma, the structural properties of collagen contribute to tumor invasion and
metastasis [99]. In normal tissue, the collagen production and assembly are regulated by the
counterbalance of matrix metalloproteinase (MMP), MMP inhibitors, and other enzymes.
The collagen in TME affects tumor cells’ proliferation, differentiation, gene expression,
migration, invasion, and metastasis. Since the MMPs in TME are more prevalent, they
degrade and remodel the basement membrane, which favors tumor cell migration and
metastasis [100]. The inhibitory effects of RSV on TGFβ and/or CXCL12-mediated myofi-
broblast phenoconversion of prostate fibroblasts in vitro [64] in a concentration-dependent
manner have been reported. Since phenoconversion is necessary for increased collagen
production [101], and increased collagen has been shown to contribute to tumor invasion
and metastasis, it is conceivable that RSV might be able to inhibit prostate cell metastasis
by preventing fibroblast to myofibroblast transition (Figure 3).
The stromal-cell–secreted MMPs play an indispensable role in cancer cell metastasis,
with MMP-2 and MMP-9 being the best-studied MMPs in prostate cancer metastasis. In
tissues with non-migrating cells, the MMPs are inhibited by tissue inhibitors of metallopro-
teinase (TIMPs). However, upregulated expressions of MMP-2 and MMP-9, accompanied
by downregulated TIMPs, were found in high-grade tumors [102], suggesting that inter-
rupting the delicate balance between MMPs and TIMPs could affect tumor cell migration
and cancer metastasis. Once secreted, both MMP-2 and MMP-9 promote metastasis by
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either enhancing the degradation of barriers of the ECM, such as collagen and laminins,
or affecting the balance between cell–cell and cell–matrix attachments [103]. Since the
inhibitory effect of RSV on MMPs has been shown in many cancer types, and RSV is capa-
ble of inhibiting both MMP-2 and MMP-9 [102], the inhibitory effect of RSV on prostate
cancer was examined in different models. The results from the animal models indicate
that RSV and the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
can act individually; the combination of them inhibits prostate cancer metastasis syner-
gistically [104]. Also, it has been noted that androgen treatment of the LNCaP cells can
morphologically alter the cells from spindle-like into fibroblast mesenchymal cell shape,
and RSV is capable of inhibiting the androgen-induced morphological change [105]. Since
this kind of morphological change usually occurs during the EMT process, it further im-
plies that RSV may play a role in prostate cancer cell EMT. In addition, it appears that RSV
is also capable of regulating the expression of cadherin. Loh et al. showed that RSV can
restore the epithelial phenotype of the mesenchymal cells and inhibit the expression of
EMT-related markers [106]. Consistently, our unpublished data also support the notion that
RSV can inhibit EMT by up- and downregulating E-cadherin and N-cadherin, respectively,
in prostate cancer cells.
4.3. Inhibitory Effects of RSV on Prostate Cancer Cell Bone Metastasis
Once escaped from their primary sites into the bloodstream, cancer cells can travel
through the blood and resettle in different organs of the body, although prostate cancer cells
preferentially metastasize to the bone. Therefore, metastatic bone cancer is the leading cause
of death for patients with prostate cancer [4]. A better understanding of the communication
between prostate cancer cells and the bone microenvironment is the first step in designing
strategies to prevent bone metastasis of prostate cancer [107].
The CXCR4/CXCL12 axis plays essential roles in all stages of prostate cancer pro-
gression [108], including bone metastasis [109]. Interaction between CXCL12 and CXCR4
leads to the activation of multiple downstream pathways such as MAPK and JNK [110]
and ultimately causes cytoskeletal rearrangements, actin polymerization, and integrin-
dependent adhesion to endothelial cells [110]. On the one hand, higher levels of CXCL12
are expressed in bone marrow stromal cells [109]. On the other hand, most prostate cancer
cells express elevated levels of CXCR4, which makes the CXCL12/CXCR4 axis more active
in these cells. Indeed, CXCL12 can enhance the adhesion of prostate cancer cells with
osteosarcoma cells [111]. In addition, Sun et al. compared the levels of CXCL12 in differ-
ent tissues and found that, in both human and mouse models, the levels of CXCL12 are
higher in the prostate cancer–preferred metastatic tissues than in those rarely targeted [112].
To further demonstrate how essential CXCR4 is to prostate cancer bone metastasis, the
authors neutralized the receptor by injecting antibodies against CXCR4 and found that
prostate-cancer-to-bone metastases were significantly inhibited [112].
Compared to the surrounding non-cancerous tissues, the vascular endothelial growth
factor (VEGF) is upregulated in most solid cancers, including prostate cancer, and one of
the major sources of VEGF in the TME is CAFs [113]. Consistently, overexpression of VEGF
receptors (VEGFR) has been found in cancerous endothelial cells, which play an indispens-
able role in cancer cell migration and metastasis [114]. More recent results indicate that the
interaction between the tumor and stromal cells can further induce HIF1α-mediated VEGF
secretion from the CAFs [38,115], which could be part of the reason why elevated levels of
VEGF are found in cancerous tissues but not the benign tissues [116]. One of the effects of
VEGF is to support tumor neovascularization through the secretion of proteolytic enzymes
to dismantle the ECM, which favors EMT [116]. The precise mechanism for VEGF-mediated
prostate cancer metastasis is not yet completely understood. But it has been hypothesized
that the bone stroma-secreted VEGF interacts with cancer cells’ VEGFR and subsequently
enhances cancer cells nesting to the bone [116]. This hypothesis is supported by the fact that
elevated levels of VEGFR-2 were consistently found on prostate cancer cells [117]. More
importantly, both VEGF and VEGFR-2 are notably higher at the sites of bone metastasis
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than at the primary prostate tumors of the same individual, further demonstrating the
importance of the VEGF/VEGFR-2 axis in prostate cancer bone metastasis [117]. Interest-
ingly, RSV and its analog HS-1793 are capable of inhibiting both hypoxia-induced VEGF
expression and prostate cancer cell migration [115] (Figure 3). In addition, RSV, either
alone or in combination with tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), can inhibit the VEGF/VEGFR2 axis in vivo [104]. RSV’s inhibitory effect in bone
stroma–prostate cancer cell communication is an ongoing research topic [116–118].
4.4. RSV Inhibits Immune Cell-Mediated Prostate Cancer Metastasis
Although the origin of tumor-associated macrophages is not completely known,
different immune cells, especially the macrophages, are found ubiquitously in solid tumors.
One school of thought is that they are tissue-resident macrophages, and another postulates
that the tumor macrophages are derived from monocytes [80,119]. Nevertheless, it is widely
accepted that immune cells not only exist in the TME but also affect the development of
prostate cancer, and multiple lines of evidence indicate that RSV is capable of inhibiting the
immune cell–mediated prostate cancer metastasis. Based on the number of macrophages
found in prostate cancer tissues derived from different patients, Lewis and colleagues
concluded that macrophages could lead to either favorable or unfavorable prognosis in
prostate cancer [120]. Later, it was found that higher tumor-associated macrophage (TAM)
count is correlated with a reduced survival time but an increased disease-free survival after
treatment [121,122]. The authors attribute this inconsistency to not only the methodological
differences between studies but also the complex functions of macrophages.
While direct evidence of RSV’s effects on macrophage activity in prostate cancer is
limited, evidence of RSV’s effects on macrophages in other cancers is well documented.
Based on their roles in tumor development, the macrophages in the tumor tissues can
be divided into either M1- or M2-like subtypes. The M1-like macrophages possess an
antitumor property by promoting Th1 response, and the M2-like macrophages usually
promote Th2 response, tissue remodeling, immune tolerance, and tumor progression [123].
TAMs are phenotypically similar to M2 macrophages [124]. Recently, Kimura et al. experi-
mentally demonstrated that RSV can prevent tumor cell metastasis by inhibiting M2-like
macrophage differentiation [125]. Consistent with the findings that prostate cancer can
secret certain factors, including IL-10, to induce M2 polarization [126], the authors further
demonstrated that RSV is capable of inhibiting M2 differentiation by downregulating
IL-10 secretion. Finally, oral administration of RSV (25 mg/kg, twice daily) for 30 days to
mice injected with the highly metastatic osteosarcoma LM8 cells significantly reduced the
number of metastatic tumors in both the lungs and the liver. These in vitro and in vivo data
altogether unambiguously demonstrate that RSV is indeed capable of inhibiting cancer cell
metastasis. However, whether RVS has a similar effect on prostate cancer cell metastasis
still needs to be determined experimentally.
5. Conclusions and Perspectives
Since its anti-inflammation and anti-oxidation activities were demonstrated experi-
mentally in 1997 [22], RSV and its derivatives have attracted great attention in both basic
science and clinical settings. Because of its beneficial effects on improved metabolism, car-
dio protection, and cancer prevention, RSV has even been widely accepted as an anti-aging
reagent. The general beneficial effects of RSV on many diseases have been thoroughly re-
viewed by Baur and Sinclair [23]. Discussion of clinical literature, along with the limitations
of preclinical and in vitro RSV studies, can be found in the review article by Tome-Carneiro
et al. [127]. The in vivo effects of resveratrol on different cancers, including breast, colorec-
tal, liver, pancreatic, and prostate cancer have been systematically reviewed by Lindsay G.
Carter [128]. More importantly, data from both in vitro and in vivo experiments indicate
that RSV is one of a few natural products with minimal adverse effects. These findings
make RSV an ideal preventive and therapeutic reagent.
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Because of the ubiquitous role of the androgen/AR axis in each process of prostate
cancer development, including initiation, progression, and metastasis, special attention
has been paid to the effects of RSV on AR. Relatively little attention has been paid to the
RSV effect on epithelium–stroma interaction, although it is well known that RSV can exert
its effects on prostate cancer in an AR-independent manner [129]. RSV has differential
effects on growth, cell cycle arrest, and induction of apoptosis by RSV in human prostate
cancer cell lines [130,131]. Overwhelming evidence suggests that RSV’s anti-prostate
cancer effect is through targeting the AR and subsequent AR-regulated genes [50,132,133].
Harada et al. reported that RSV represses AR target gene expression, at least partially,
by enhancing AR degradation in a time- and dose-dependent manner [134]. Along with
other groups, we have demonstrated that RSV can repress AR function by inhibiting
AR transcriptional activity [135]. In addition, a group of ~20 AR variants (ARVs) has
been identified in prostate cancer, especially the metastatic castration-resistant prostate
cancer (mCRPC). Among these variants, ARV7 has attracted special attention because
of its androgen-independent transcriptional activity [136]. More recent findings suggest
that approximately 10–30% of men with mCRPC are positive for AR-V7 [137]. We have
also demonstrated that RSV is capable of repressing mCRPC cell growth by enhancing
ARV7 poly-ubiquitination and subsequent degradation [138]. These findings suggest that
resveratrol could be used as a prostate cancer preventive or therapeutic reagent.
Given the emerging roles of the stromal cells in cancer initiation and progression,
great attention has been paid to the communication between stromal and cancer cells
in recent years. Mounting evidence indicates that the stromal cells play indispensable
roles in prostate cancer initiation, proliferation, and metastasis. As we have discussed
in this review, by interrupting the epithelial and stromal cell communication, RSV can
inhibit prostate cancer development through different mechanisms. However, there are still
many unanswered questions about how RSV affects stromal–cancer cell communication.
For example, it is well established that AR is expressed and functional in both epithelial
and stromal cells [11]. But compared to our understanding of RSV’s effect on epithelial
cells, very little is known about the role of RSV in stromal cells. Besides, ARV7 plays an
indispensable role in mCRPC, and resveratrol can inhibit the proliferation of AVR7-positive
cells. Our unpublished data indicate that RSV can affect the E-cadherin and N-cadherin
ratio in ARV7-positive prostate cancer cells, suggesting that RSV could potentially be able
to affect the metastasis of these cells. Whether ARV7 is simultaneously or subsequently
expressed in cancer and stromal cells is unknown. If ARV7 is indeed expressed in stromal
cells, will RSV also affect the stromal cells through targeting ARV7 as it did in the cancer
cells? Answers to these questions and a better understanding of the underlying molecular
mechanisms in how RSV inhibits prostate cancer progression by interrupting stromal–
cancer cell communication will pave the road toward the application of RSV as both a
cancer preventive and therapeutic reagent.
Funding: This research was funded by the Philadelphia College of Osteopathic Medicine.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Ferlay, J.; Soejomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef]
2. Humphrey, P.A. Histopathology of prostate cancer. Cold Spring Harbor Perspect. Med. 2017, 7, a030411. [CrossRef] [PubMed]
3. Lu-Yao, G.L.; Albertsen, P.C.; Moore, D.F.; Shih, W.; Lin, Y.; DiPaola, R.S.; Barry, M.J.; Zietman, A.; O’Leary, M.;
Walker-Corkery, E.; et al. Outcomes of localized prostate cancer following conservative management. JAMA J. Am. Med
Assoc. 2009, 302, 1202–1209. [CrossRef] [PubMed]
4. Wang, N.; Docherty, F.E.; Brown, H.K.; Reeves, K.J.; Fowles, A.C.M.; Ottewell, P.D.; Dear, T.N.; Holen, I.; Croucher, P.I.; Eaton, C.L.
Prostate cancer cells preferentially home to osteoblast rich areas in the early stages of bone metastasis: Evidence from in vivo
models. J. Bone Miner. Res. 2014, 29, 2688–2696. [CrossRef] [PubMed]
J. Xenobiot. 2021, 11 27
5. Shafi, A.A.; Yen, A.E.; Weigel, N.L. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Pharmacol. Ther. 2013, 140, 223–238. [CrossRef]
6. Pandini, G.; Mineo, R.; Frasca, F.; Roberts, C.T., Jr.; Marcelli, M.; Vigneri, R.; Belfiore, A. Androgens up-regulate the insulin-like
growth factor-I receptor in prostate cancer cells. Cancer Res. 2005, 65, 1849–1857. [CrossRef]
7. Cao, R.; Ke, M.; Wu, Q.; Tian, Q.; Liu, L.; Dai, Z.; Lu, S.; Liu, P. AZGP1 is androgen responsive and involved in AR induced
prostate cancer cell proliferation and metastasis. J. Cell Physiol. 2019, 234, 17444–17458. [CrossRef]
8. Wen, S.; Niu, Y.; Lee, S.O.; Chang, C. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including
apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev. 2014, 40, 31–40. [CrossRef]
9. Thalmann, G.N.; Rhee, H.; Sikes, R.A.; Pathak, S.; Multani, A.; Zhau, H.E.; Marshall, F.F.; Chunge, L.W.K. Human prostate
fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP cells. Eur. Urol. 2009, 58, 162–172.
[CrossRef]
10. Bonollo, F.; Thalmann, G.N.; Kruithof-de Julio, M.; Karkampouna, S. The role of cancer-associated fibroblasts in prostate cancer
tumorigenesis. Cancers 2020, 12, 1887. [CrossRef]
11. Cioni, B.; Zwart, W.; Bergman, A.M. Androgen receptor moonlighting in the prostate cancer microenvironment. Endocr. Relat. Cancer
2018, 25, R331–R349. [CrossRef] [PubMed]
12. Bissell, M.J.; Radisky, D. Putting tumours in context. Nat. Rev. Cancer 2001, 1, 46–54. [CrossRef] [PubMed]
13. Olumi, A.F.; Grossfeld, G.D.; Hayward, S.W.; Carroll, P.R.; Tlsty, T.D.; Cunha, G.R. Carcinoma-associated fibroblasts direct tumor
progression of initiated human prostatic epithelium. Cancer Res. 1999, 59, 5002–5011.
14. Lai, K.; Yamashita, S.; Huang, C.; Yeh, S.; Chang, C. Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis
via modulation of pro-inflammatory cytokines/chemokines. EMBO Mol. Med. 2012, 4, 791–807. [CrossRef] [PubMed]
15. Wikström, P.; Marusic, J.; Stattin, P.; Bergh, A. Low stroma androgen receptor level in normal and tumor prostate tissue is related
to poor outcome in prostate cancer patients. Prostate 2009, 69, 799–809. [CrossRef]
16. Herden, J.; Weissbach, L. Utilization of active surveillance and watchful waiting for localized prostate cancer in the daily practice.
World J. Urol. 2018, 36, 383–391. [CrossRef]
17. Crawford, E.D.; Heidenreich, A.; Lawrentschuk, N.; Tombal, B.; Pompeo, A.C.L.; Mendoza-Valdes, A.; Miller, K.; Debruyne, F.M.J.;
Klotz, L. Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations. Prostate Cancer
Prostatic Dis. 2018, 22, 24–38. [CrossRef]
18. De Amicis, F.; Chimento, A.; Montalto, F.I.; Casaburi, I.; Sirianni, R.; Pezzi, V. Steroid receptor signallings as targets for resveratrol
actions in breast and prostate cancer. Int. J. Mol. Sci. 2019, 20, 1087. [CrossRef]
19. Chandrasekar, T.; Yang, J.C.; Gao, A.C.; Evans, C.P. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Transl. Androl. Urol. 2015, 4, 365–380. [CrossRef]
20. Auchus, R.J. The backdoor pathway to dihydrotestosterone. Trends Endocrinol. Metab. 2004, 15, 432–438. [CrossRef]
21. Guerrero, J.; Alfaro, I.E.; Gómez, F.; Protter, A.A.; Bernales, S. Enzalutamide, an androgen receptor signaling inhibitor, induces
tumor regression in a mouse model of castration-resistant prostate cancer. Prostate 2013, 73, 1291–1305. [CrossRef] [PubMed]
22. Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.W.; Fong, H.H.S.; Farnsworth, N.R.; Kinghorn, A.D.;
Mehta, R.G.; et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997,
275, 218–220. [CrossRef] [PubMed]
23. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006, 5, 493–506.
[CrossRef] [PubMed]
24. Chakraborty, S.; Kumar, A.; Butt, N.A.; Zhang, L.; Williams, R.; Rimando, A.M.; Biswas, P.K.; Levenson, A.S. Molecular insight
into the differential anti-androgenic activity of resveratrol and its natural analogs: In silico approach to understand biological
actions. Mol. Biosyst. 2016, 12, 1702–1709. [CrossRef] [PubMed]
25. Lee, M.H.; Kundu, J.K.; Keum, Y.S.; Cho, Y.Y.; Surh, Y.J.; Choi, B.Y. Resveratrol inhibits IL-6-induced transcriptional activity of AR
and STAT3 in human prostate cancer LNCaP-FGC cells. Biomol. Ther. 2014, 22, 426–430. [CrossRef]
26. Vancauwenberghe, E.; Noyer, L.; Derouiche, S.; Lemonnier, L.; Gosset, P.; Sadofsky, L.R.; Mariot, P.; Warnier, M.; Bokhobza, A.;
Slomianny, C.; et al. Activation of mutated TRPA1 ion channel by resveratrol in human prostate cancer associated fibroblasts
(CAF). Mol. Carcinog. 2017, 56, 1851–1867. [CrossRef]
27. Martínez-Martínez, D.; Soto, A.; Gil-Araujo, B.; Gallego, B.; Chiloeches, A.; Lasa, M. Resveratrol promotes apoptosis through the
induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin. Food Chem. Toxicol. 2019, 124, 273–279.
[CrossRef]
28. Kai, L.; Levenson, A.S. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor
inhibition in prostate cancer cells. Anticancer Res. 2011, 31, 3323.
29. Franks, L.M.; Riddle, P.N.; Carbonell, A.W.; Gey, G.O. A comparative study of the ultrastructure and lack of growth capacity of
adult human prostate epithelium mechanically separated from its stroma. J. Pathol. 1970, 100, 113–119. [CrossRef]
30. Chung, L.W.; Chang, S.M.; Bell, C.; Zhau, H.E.; Ro, J.Y.; von Eschenbach, A.C. Co-inoculation of tumorigenic rat prostate
mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic
animals. Int. J. Cancer 1989, 43, 1179–1187. [CrossRef]
J. Xenobiot. 2021, 11 28
31. Marker, P.C.; Donjacour, A.A.; Dahiya, R.; Cunha, G.R. Hormonal, cellular, and molecular control of prostatic development.
Dev. Biol. 2003, 253, 165–174. [CrossRef]
32. Miah, S.; Catto, J. BPH and prostate cancer risk. Indian J. Urol. 2014, 30, 214–218. [CrossRef] [PubMed]
33. Ao, M.; Franco, O.E.; Park, D.; Raman, D.; Williams, K.; Hayward, S.W. Cross-talk between paracrine-acting cytokine and
chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 2007, 67, 4244–4253. [CrossRef]
[PubMed]
34. Leach, D.; Buchanan, G. Stromal androgen receptor in prostate cancer development and progression. Cancers 2017, 9, 10.
[CrossRef]
35. Barron, D.A.; Rowley, D.R. The reactive stroma microenvironment and prostate cancer progression. Endocr. Relat. Cancer 2012,
19, R187–R204. [CrossRef]
36. Cunha, G.R.; Hayward, S.W.; Wang, Y.Z. Role of stroma in carcinogenesis of the prostate. Differentiation 2002, 70, 473–485.
[CrossRef]
37. Singh, S.; Singh, U.P.; Grizzle, W.E.; Lillard, J.W., Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration,
metalloproteinase expression and invasion. Lab. Investig. 2004, 84, 1666–1676. [CrossRef]
38. Tao, L.; Huang, G.; Song, H.; Chen, Y.; Chen, L. Cancer associated fibroblasts: An essential role in the tumor microenvironment.
Oncol. Lett. 2017, 14, 2611–2620. [CrossRef]
39. Shaw, A.K.; Pickup, M.W.; Chytil, A.; Aakre, M.; Owens, P.; Moses, H.L.; Novitskiy, S.V. TGFβ signaling in myeloid cells regulates
mammary carcinoma cell invasion through fibroblast interactions. PLoS ONE 2015, 10, e0117908. [CrossRef]
40. Schoonen, W.M.; Salinas, C.A.; Kiemeney, L.A.; Stanford, J.L. Alcohol consumption and risk of prostate cancer in middle-aged
men. Int. J. Cancer 2005, 113, 133–140. [CrossRef]
41. Feitelson, M.A.; Arzumanyan, A.; Kulathinal, R.J.; Blain, S.W.; Holcombe, R.F.; Mahajna, J.; Marino, M.; Martinez-Chantar, M.L.;
Nawroth, R.; Sanchez-Garcia, I.; et al. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.
Semin Cancer Biol. 2015, 35, S25–S54. [CrossRef] [PubMed]
42. He, Y.; Zeng, H.; Yu, Y.; Zhang, J.; Liu, Q.; Yang, B. Resveratrol improved detrusor fibrosis induced by mast cells during
progression of chronic prostatitis in rats. Eur. J. Pharmacol. 2017, 815, 495–500. [CrossRef] [PubMed]
43. Guo, J.; Zhou, J.; Zhao, Y.; Liu, P.Y.; Yao, H.J.; Da, J.; Zhang, M.; Zhou, Z.; Chen, Q.; Peng, Y.B.; et al. Normal peripheral prostate
stromal cells stimulate prostate cancer development: Roles of c-kit signal. Am. J. Transl. Res. 2015, 7, 502–512. [CrossRef]
[PubMed]
44. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
45. Sung, S.; Chung, L.W.K. Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting.
Differentiation 2002, 70, 506–521. [CrossRef] [PubMed]
46. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6, 392–401. [CrossRef] [PubMed]
47. Nakagawa, H.; Liyanarachchi, S.; Davuluri, R.V.; Auer, H.; Martin Jr, E.W.; de la Chapelle, A.; Frankel, W.L. Role of cancer-
associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene 2004, 23, 7366–7377.
[CrossRef]
48. Owens, G.K. Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 1995, 75, 487–517. [CrossRef]
49. Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 2016, 16, 582–598. [CrossRef]
50. Wang, T.T.; Hudson, T.S.; Wang, T.C.; Remsberg, C.M.; Davies, N.M.; Takahashi, Y.; Kim, Y.S.; Seifried, H.; Vinyard, B.T.;
Perkins, S.N.; et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and
in vivo. Carcinogenesis 2008, 29, 2001–2010. [CrossRef]
51. Harper, C.E.; Patel, B.B.; Wang, J.; Arabshahi, A.; Eltoum, I.A.; Lamartiniere, C.A. Resveratrol suppresses prostate cancer
progression in transgenic mice. Carcinogenesis 2007, 28, 1946–1953. [CrossRef] [PubMed]
52. Johnson, D.E.; O’Keefe, R.A.; Grandis, J.R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 2018,
15, 234–248. [CrossRef] [PubMed]
53. Carpenter, R.L.; Lo, H.W. STAT3 target genes relevant to human cancers. Cancers 2014, 6, 897–925. [CrossRef] [PubMed]
54. Reed, J.C.; Zha, H.; Aime-Sempe, C.; Takayama, S.; Wang, H.G. Structure-function analysis of bcl-2 family proteins. regulators of
programmed cell death. Adv. Exp. Med. Biol. 1996, 406, 99–112. [PubMed]
55. Twillie, D.A.; Eisenberger, M.A.; Carducci, M.A.; Hseih, W.S.; Kim, W.Y.; Simons, J.W. Interleukin-6: A candidate mediator of
human prostate cancer morbidity. Urology 1995, 45, 542–549. [CrossRef]
56. Chung, L.W.; Baseman, A.; Assikis, V.; Zhau, H.E. Molecular insights into prostate cancer progression: The missing link of tumor
microenvironment. J. Urol. 2005, 173, 10–20. [CrossRef]
57. Cheteh, E.H.; Sarne, V.; Ceder, S.; Bianchi, J.; Augsten, M.; Rundqvist, H.; Egevad, L.; Östman, A.; Wiman, K.G. Interleukin-6
derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discov.
2020, 6, 42–45. [CrossRef]
58. Guo, Y.; Xu, F.; Lu, T.; Duan, Z.; Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012,
38, 904–910. [CrossRef]
J. Xenobiot. 2021, 11 29
59. Hobisch, A.; Eder, I.E.; Putz, T.; Horninger, W.; Bartsch, G.; Klocker, H.; Culig, Z. Interleukin-6 regulates prostate-specific protein
expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998, 58, 4640–4645.
60. van der Poel, H.G.; Zevenhoven, J.; Bergman, A.M. Pim1 regulates androgen-dependent survival signaling in prostate cancer
cells. Urol. Int. 2010, 84, 212–220. [CrossRef]
61. Ha, S.; Iqbal, N.J.; Mita, P.; Ruoff, R.; Gerald, W.L.; Lepor, H.; Taneja, S.S.; Lee, P.; Melamed, J.; Garabedian, M.J.; et al.
Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene 2013, 32, 3992–4000.
[CrossRef] [PubMed]
62. Zemskova, M.; Sahakian, E.; Bashkirova, S.; Lilly, M. The PIM1 kinase is a critical component of a survival pathway activated
by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J. Biol. Chem. 2008, 283, 20635–20644. [CrossRef]
[PubMed]
63. Kampan, N.C.; Xiang, S.D.; McNally, O.M.; Stephens, A.N.; Quinn, M.A.; Plebanski, M. Immunotherapeutic interleukin-6 or
interleukin-6 receptor blockade in cancer: Challenges and opportunities. Curr. Med. Chem. 2018, 25, 4785–4806. [CrossRef]
[PubMed]
64. Gharaee-Kermani, M.; Moore, B.B.; Macoska, J.A. Resveratrol-mediated repression and reversion of prostatic myofibroblast
phenoconversion. PLoS ONE 2016, 11, e0158357. [CrossRef] [PubMed]
65. Lin, M.T.; Yen, M.L.; Lin, C.Y.; Kuo, M.L. Inhibition of vascular endothelial growth factor-induced angiogenesis by resver-
atrol through interruption of src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol. Pharmacol. 2003,
64, 1029–1036. [CrossRef]
66. Al Aameri, R.F.H.; Sheth, S.; Alanisi, E.M.A.; Borse, V.; Mukherjea, D.; Rybak, L.P.; Ramkumar, V. Tonic suppression of PCAT29 by
the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol. PLoS ONE 2017, 12, e0177198. [CrossRef]
67. Epling-Burnette, P.K.; Liu, J.H.; Catlett-Falcone, R.; Turkson, J.; Oshiro, M.; Kothapalli, R.; Li, Y.; Wang, J.-M.; Yang-Yen, H.-F.;
Karras, J.; et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased mcl-1
expression. J. Clin. Investig. 2001, 107, 351–362. [CrossRef]
68. Sinibaldi, D.; Wharton, W.; Turkson, J.; Bowman, T.; Pledger, W.J.; Jove, R. Induction of p21WAF1/CIP1 and cyclin D1 expression
by the src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling. Oncogene 2000, 19, 5419–5427. [CrossRef]
69. Parkins, C.S.; Stratford, M.R.; Dennis, M.F.; Stubbs, M.; Chaplin, D.J. The relationship between extracellular lactate and tumour
pH in a murine tumour model of ischaemia-reperfusion. Br. J. Cancer 1997, 75, 319–323. [CrossRef]
70. Deep, G.; Panigrahi, G.K. Hypoxia-induced signaling promotes prostate cancer progression: Exosomes role as messenger of
hypoxic response in tumor microenvironment. Crit. Rev. Oncog. 2015, 20, 419–434. [CrossRef]
71. Fraga, A.; Ribeiro, R.; Principe, P.; Lopes, C.; Medeiros, R. Hypoxia and prostate cancer aggressiveness: A tale with many endings.
Clin. Genitourin Cancer 2015, 13, 295–301. [CrossRef] [PubMed]
72. Lenaz, G. The mitochondrial production of reactive oxygen species: Mechanisms and implications in human pathology.
IUBMB Life 2001, 52, 159–164. [CrossRef] [PubMed]
73. Hoffman, D.L.; Salter, J.D.; Brookes, P.S. Response of mitochondrial reactive oxygen species generation to steady-state oxygen
tension: Implications for hypoxic cell signaling. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, 101. [CrossRef] [PubMed]
74. Chandel, N.S.; Maltepe, E.; Goldwasser, E.; Mathieu, C.E.; Simon, M.C.; Schumacker, P.T. Mitochondrial reactive oxygen species
trigger hypoxia-induced transcription. Proc. Natl. Acad. Sci. USA 1998, 95, 11715–11720. [CrossRef] [PubMed]
75. Gorlach, A.; Kietzmann, T. Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors.
Methods Enzymol. 2007, 435, 421–446. [CrossRef]
76. Rodriguez-Enriquez, S.; Pacheco-Velazquez, S.C.; Marin-Hernandez, A.; Gallardo-Pérez, J.C.; Robledo-Cadena, D.X.; Hernández-
Reséndiz, I.; García-García, J.D.; Belmont-Díaz, J.; López-Marure, R.; Hernández-Esquivel, L.; et al. Resveratrol inhibits cancer
cell proliferation by impairing oxidative phosphorylation and inducing oxidative stress. Toxicol. Appl. Pharmacol. 2019, 370, 65–77.
[CrossRef]
77. Kovacic, P.; Somanathan, R. Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and
safety. Oxid. Med. Cell Longev. 2010, 3, 86–100. [CrossRef]
78. Mancuso, R.; del Valle, J.; Modol, L.; Martinez, A.; Granado-Serrano, A.B.; Ramirez-Núñez, O.; Pallás, M.; Portero-Otin, M.;
Osta, R.; Navarro, X. Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics
2014, 11, 419–432. [CrossRef]
79. Shi, Y.; Zhou, J.; Jiang, B.; Miao, M. Resveratrol and inflammatory bowel disease. Ann. N. Y. Acad. Sci. 2017, 1403, 38–47.
[CrossRef]
80. Zhang, J.; Patel, L.; Pienta, K.J. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.
Cytokine Growth Factor Rev. 2010, 21, 41–48. [CrossRef]
81. Shamim, U.; Hanif, S.; Albanyan, A.; Beck, F.W.J.; Bao, B.; Wang, Z.; Banerjee, S.; Sarkar, F.H.; Mohammad, R.M.; Hadi, S.M.; et al.
Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. J. Cell Physiol. 2012, 227, 1493–1500.
[CrossRef] [PubMed]
J. Xenobiot. 2021, 11 30
82. Muqbil, I.; Beck, F.W.; Bao, B.; Sarkar, F.H.; Mohammad, R.M.; Hadi, S.M.; Azmi, A.S. Old wine in a new bottle: The warburg
effect and anticancer mechanisms of resveratrol. Curr. Pharm. Des. 2012, 18, 1645–1654. [CrossRef] [PubMed]
83. Zheng, L.F.; Wei, Q.Y.; Cai, Y.J.; Fang, J.G.; Zhou, B.; Yang, L.; Liu, Z.-L. DNA damage induced by resveratrol and its synthetic
analogues in the presence of cu (II) ions: Mechanism and structure-activity relationship. Free Radic. Biol. Med. 2006, 41, 1807–1816.
[CrossRef] [PubMed]
84. Wang, D.; Gao, Z.; Zhang, X. Resveratrol induces apoptosis in murine prostate cancer cells via hypoxia-inducible factor 1-alpha
(HIF-1alpha)/reactive oxygen species (ROS)/P53 signaling. Med. Sci. Monit. 2018, 24, 8970–8976. [CrossRef] [PubMed]
85. Andreyev, A.Y.; Kushnareva, Y.E.; Starkov, A.A. Mitochondrial metabolism of reactive oxygen species. Biochemistry 2005,
70, 200–214. [CrossRef]
86. Low, I.C.; Chen, Z.X.; Pervaiz, S. Bcl-2 modulates resveratrol-induced ROS production by regulating mitochondrial respiration in
tumor cells. Antioxid. Redox. Signal. 2010, 13, 807–819. [CrossRef]
87. Niu, Y.N.; Xia, S.J. Stroma-epithelium crosstalk in prostate cancer. Asian J. Androl. 2009, 11, 28–35. [CrossRef]
88. Xia, N.; Daiber, A.; Forstermann, U.; Li, H. Antioxidant effects of resveratrol in the cardiovascular system. Br. J. Pharmacol. 2017,
174, 1633–1646. [CrossRef]
89. Li, J.; Chong, T.; Wang, Z.; Chen, H.; Li, H.; Cao, J.; Zhang, P.; Li, H. A novel anti-cancer effect of resveratrol: Reversal of
epithelial-mesenchymal transition in prostate cancer cells. Mol. Med. Rep. 2014, 10, 1717–1724. [CrossRef]
90. Varkaris, A.; Corn, P.G.; Gaur, S.; Dayyani, F.; Logothetis, C.J.; Gallick, G.E. The role of HGF/c-met signaling in prostate cancer
progression and c-met inhibitors in clinical trials. Expert Opin. Investig. Drugs 2011, 20, 1677–1684. [CrossRef]
91. Gmyrek, G.A.; Walburg, M.; Webb, C.P.; Yu, H.M.; You, X.; Vaughan, E.D.; Vande Woude, G.F.; Knudsen, B.S. Normal and
malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am. J. Pathol. 2001,
159, 579–590. [CrossRef]
92. Hsieh, T.C.; Wu, J.M. Resveratrol suppresses prostate cancer epithelial cell scatter/invasion by targeting inhibition of hepatocyte
growth factor (HGF) secretion by prostate stromal cells and upregulation of E-cadherin by prostate cancer epithelial cells. Int. J.
Mol. Sci. 2020, 21, 1760. [CrossRef] [PubMed]
93. Yu, L.; Wang, S.; Kogure, Y.; Yamamoto, S.; Noguchi, K.; Dai, Y. Modulation of TRP channels by resveratrol and other stilbenoids.
Mol. Pain 2013, 9, 3. [CrossRef] [PubMed]
94. Nalli, M.; Ortar, G.; Moriello, A.S.; Morera, E.; Di Marzo, V.; De Petrocellis, L. TRPA1 channels as targets for resveratrol and
related stilbenoids. Bioorganic Med. Chem. Lett. 2016, 26, 899–902. [CrossRef] [PubMed]
95. Tuxhorn, J.A.; Ayala, G.E.; Smith, M.J.; Smith, V.C.; Dang, T.D.; Rowley, D.R. Reactive stroma in human prostate cancer: Induction
of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 2002, 8, 2912–2923.
96. Xu, S.; Xu, H.; Wang, W.; Li, S.; Li, H.; Li, T.; Zhang, W.; Yu, X.; Liu, L. The role of collagen in cancer: From bench to bedside.
J. Transl. Med. 2019, 17, 1–22. [CrossRef]
97. Putzke, A.P.; Ventura, A.P.; Bailey, A.M.; Akture, C.; Opoku-Ansah, J.; Çeliktaş, M.; Hwang, M.S.; Darling, D.S.; Coleman, I.M.;
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